Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
— Series C supported by premier syndicate including co-leads Ascenta Capital and Janus Henderson Investors with significant participation from Deep Track plus existing investors — — Fundingenables larger Phase 2 clinical proof-of-concept trial evaluating IL-13 and KLK5/7 dual-targeting...
— Series C supported by premier syndicate including co-leads Ascenta Capital and Janus Henderson Investors with significant participation from Deep Track plus existing investors — — Fundingenables larger Phase 2 clinical proof-of-concept trial evaluating IL-13 and KLK5/7 dual-targeting...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.